
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …

The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

